Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Adriamycin and Cytoxan (AC)|DRUG: ABI-007|DRUG: Taxol|DRUG: Bevacizumab|DRUG: pegfilgrastim
Sponsor: Celgene